First results of a Phase 1 study evaluating safety, PK, PD and clinical activity of STC-15, a METTL3 inhibitor, in patients with advanced malignancies, October 2024, EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics 2024

Jordi Rodon Ahnert¹, Justin C Moser², Kyriakos P. Papadopoulos³, Yaara Ofir-Rosenfeld⁴, Hendrik Weisser⁴, Melinda Snyder⁴, Tess Schmalbach⁴, Tess Barker⁴, Deepa Deshpande⁴, Ben Skead⁴, Doug Hester², Nidhi Sheth², Pamela Saldana Leon¹, Edwin Blanco-Cepeda³, Oliver Rausch⁴, Josefin-Beate Holz⁴

¹Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX
² HonorHealth Research Institute, Scottsdale, AZ
³ START San Antonio, San Antonio, TX
⁴ Storm Therapeutics Ltd, Cambridge, United Kingdom

Download poster